US Stock Market Movement | AI pharmaceutical company Iambic Therapeutics (IAM.US), supported by Nvidia, goes public on Nasdaq and surges over 11% after opening

Zhihu Finance APP reports that on Thursday, Iambic Therapeutics (IAM.US), an AI pharmaceutical company backed by Nvidia, debuted on Nasdaq. As of press time, the stock had surged over 11% to $17.77, triggering the exchange's circuit breaker mechanism. The IPO price was $16. Iambic Therapeutics is a clinical-stage biotechnology company that combines proprietary AI models with automated high-throughput chemistry and biology to design small molecule drugs. The platform operates via a closed-loop process: its models propose compound solutions, and the robotic laboratory synthesizes and tests hundreds of compounds per project each week. The resulting data is then used to retrain the models. Its main candidate drug IAM1363 is a selective, blood-brain barrier-penetrating HER2 inhibitor, currently undergoing Phase 1/1b clinical trials for solid tumors with HER2 alterations, with registrational trials possibly starting as early as 2027. Two other preclinical programs targeting KIF18A and CDK2/4 are expected to submit IND applications in the fourth quarter. To date, Iambic Therapeutics has generated revenue through collaborations with companies such as AbbVie (ABBV.US), Takeda Pharmaceutical (TAK.US), and Bayer (BAYRY.US).